Why Ocugen (OCGN) Shares Are Trading Higher Premarket Today? - Ocugen (NASDAQ:OCGN)

Ocugen Inc OCGN announced results from the Phase 2/3 study of its COVID-19 vaccine candidate, COVAXIN.
COVAXIN has been demonstrated in clinical trials to generate a broader immune response against the whole virus covering important antigens such as S-protein, RBD, and N-protein, whereas currently approved vaccines in the U.S. target only S-protein antigens.
In contrast to other inactivated vaccines, trials have demonstrated that TLR7/8 agonist adjuvant in COVAXIN generates a Th1-biased immune response that induces robust long-term memory B- and T-cell responses.
Related: Ocugen Inks US Development Pact For Its Intranasal COVID-19 Vaccine.
Both co-primary immunogenicity endpoints were met well above the non-inferiority limit with robust immune responses.
Covaxin was found to be well-tolerated in vaccine-naïve individuals and individuals previously vaccinated with mRNA vaccines in the U.S., with no vaccine-related serious adverse events, thrombotic events, or cases of myocarditis or pericarditis.
Price Action: OCGN shares are up 20.8% at $1.57 during the premarket session on the last check Monday.

Ocugen Announces Encouraging Data From Late-Stage COVID-19 Vaccine Study